{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T06:58:31Z","timestamp":1792652311893,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T00:00:00Z","timestamp":1586908800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013227","name":"Health Promotion Administration, Ministry of Health and Welfare","doi-asserted-by":"crossref","award":["HI15C1592"],"award-info":[{"award-number":["HI15C1592"]}],"id":[{"id":"10.13039\/100013227","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100010239","name":"Korea Carbon Capture and Sequestration R and D Center","doi-asserted-by":"crossref","award":["HI13C2162"],"award-info":[{"award-number":["HI13C2162"]}],"id":[{"id":"10.13039\/501100010239","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>We investigated whether head and neck squamous cell carcinoma (HNSCC) patient-derived xenografts (PDXs) reaffirm patient responses to anti-cancer therapeutics.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Tumors from HNSCC patients were transplanted into immunodeficient mice and propagated via subsequent implantation. We evaluated established PDXs by histology, genomic profiling, and in vivo anti-cancer efficacy testing to confirm them as the authentic in vivo platform.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>From 62 HNSCCs, 15 (24%) PDXs were established. The primary cancer types were tongue (8), oropharynx (3), hypopharynx (1), ethmoid sinus cancer (1), supraglottic cancer (1), and parotid gland (1); six PDXs (40%) were established from biopsy specimens from advanced HNSCC. PDXs mostly retained donor characteristics and remained stable across passages. <jats:italic>PIK3CA<\/jats:italic> (H1047R), <jats:italic>HRAS<\/jats:italic> (G12D), and <jats:italic>TP53<\/jats:italic> mutations (H193R, I195T, R248W, R273H, E298X) and <jats:italic>EGFR<\/jats:italic>, <jats:italic>CCND1<\/jats:italic>, <jats:italic>MYC<\/jats:italic>, and <jats:italic>PIK3CA<\/jats:italic> amplifications were identified. Using the acquisition method, biopsy showed a significantly higher engraftment rate when compared with that of surgical resection (100% [6\/6] vs. 16.1% [9\/56], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Specimens obtained from metastatic sites showed a significantly higher engraftment rate than did those from primary sites (100% [9\/9] vs. 11.3% [6\/53], <jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001). Three PDX models from HPV-positive tumors were established, as compared to 12 from HPV-negative (15.8% [3\/19] and 27.9% [12\/43] respectively, <jats:italic>P<\/jats:italic>\u2009=\u20090.311), suggesting that HPV positivity tends to show a low engraftment rate. Drug responses in PDX recapitulated the clinical responses of the matching patients with pan-HER inhibitors and pan-PI3K inhibitor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Genetically and clinically annotated HNSCC PDXs could be useful preclinical tools for evaluating biomarkers, therapeutic targets, and new drug discovery.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12885-020-06786-5","type":"journal-article","created":{"date-parts":[[2020,4,15]],"date-time":"2020-04-15T13:03:53Z","timestamp":1586955833000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Establishment and characterization of patient-derived xenografts as paraclinical models for head and neck cancer"],"prefix":"10.1186","volume":"20","author":[{"given":"Han Na","family":"Kang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae-Hwan","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A-Young","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Woo","family":"Choi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Min","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinna","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eun Joo","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min Hee","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyoung-Ho","family":"Pyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi Ran","family":"Yun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Hwi","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanna","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Och","family":"Yoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da Hee","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Young Min","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyung Kwon","family":"Byeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inkyung","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soonmyung","family":"Paik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoon Woo","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Byoung Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Ryun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,4,15]]},"reference":[{"issue":"1","key":"6786_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1158\/2326-6066.CIR-14-0205","volume":"3","author":"JD Schoenfeld","year":"2015","unstructured":"Schoenfeld JD. Immunity in head and neck cancer. Cancer Immunol Res. 2015;3(1):12\u20137.","journal-title":"Cancer Immunol Res"},{"issue":"25","key":"6786_CR2","doi-asserted-by":"publisher","first-page":"3217","DOI":"10.1038\/onc.2015.424","volume":"35","author":"SM Parsel","year":"2016","unstructured":"Parsel SM, Grandis JR, Thomas SM. Nucleic acid targeting: towards personalized therapy for head and neck cancer. Oncogene. 2016;35(25):3217\u201326.","journal-title":"Oncogene"},{"issue":"14","key":"6786_CR3","doi-asserted-by":"publisher","first-page":"4372","DOI":"10.1158\/0008-5472.CAN-12-3342","volume":"73","author":"OD Abaan","year":"2013","unstructured":"Abaan OD, Polley EC, Davis SR, Zhu YJ, Bilke S, Walker RL, Pineda M, Gindin Y, Jiang Y, Reinhold WC, et al. The exomes of the NCI-60 panel: a genomic resource for cancer biology and systems pharmacology. Cancer Res. 2013;73(14):4372\u201382.","journal-title":"Cancer Res"},{"issue":"10","key":"6786_CR4","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/nrc1951","volume":"6","author":"RH Shoemaker","year":"2006","unstructured":"Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer. 2006;6(10):813\u201323.","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"6786_CR5","doi-asserted-by":"publisher","first-page":"e0142429","DOI":"10.1371\/journal.pone.0142429","volume":"10","author":"M Fritsch","year":"2015","unstructured":"Fritsch M, Schmidt N, Groticke I, Frisk AL, Keator CS, Koch M, Slayden OD. Application of a patient derived Xenograft model for predicative study of uterine fibroid disease. PLoS One. 2015;10(11):e0142429.","journal-title":"PLoS One"},{"issue":"4","key":"6786_CR6","doi-asserted-by":"publisher","first-page":"480","DOI":"10.7705\/biomedica.v35i4.2386","volume":"35","author":"M Griffith","year":"2015","unstructured":"Griffith M, Rovira J, Torres R, Calzada J, Victoria C, Caceres L. knowledge, attitudes and practices regarding malaria in the indigenous Guna population of the Madungandi region, Panama, 2012. Biomedica. 2015;35(4):480\u201395.","journal-title":"Biomedica"},{"key":"6786_CR7","doi-asserted-by":"crossref","unstructured":"Williams JA. Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field. J Clin Med. 2018;7(3):41.","DOI":"10.3390\/jcm7030041"},{"key":"6786_CR8","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.lungcan.2018.08.008","volume":"124","author":"HN Kang","year":"2018","unstructured":"Kang HN, Choi JW, Shim HS, Kim J, Kim DJ, Lee CY, Hong MH, Park SY, Park AY, Shin EJ, et al. Establishment of a platform of non-small-cell lung cancer patient-derived xenografts with clinical and genomic annotation. Lung Cancer (Amsterdam, Netherlands). 2018;124:168\u201378.","journal-title":"Lung Cancer (Amsterdam, Netherlands)"},{"issue":"6","key":"6786_CR9","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/carcin\/bgh148","volume":"25","author":"MD Westfall","year":"2004","unstructured":"Westfall MD, Pietenpol JA. p63: molecular complexity in development and cancer. Carcinogenesis. 2004;25(6):857\u201364.","journal-title":"Carcinogenesis"},{"key":"6786_CR10","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1186\/1479-5876-11-198","volume":"11","author":"S Peng","year":"2013","unstructured":"Peng S, Creighton CJ, Zhang Y, Sen B, Mazumdar T, Myers JN, Lai SY, Woolfson A, Lorenzi MV, Bell D, et al. Tumor grafts derived from patients with head and neck squamous carcinoma authentically maintain the molecular and histologic characteristics of human cancers. J Transl Med. 2013;11:198.","journal-title":"J Transl Med"},{"issue":"12","key":"6786_CR11","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/ijc.29344","volume":"136","author":"K Klinghammer","year":"2015","unstructured":"Klinghammer K, Raguse JD, Plath T, Albers AE, Joehrens K, Zakarneh A, Brzezicha B, Wulf-Goldenberg A, Keilholz U, Hoffmann J, et al. A comprehensively characterized large panel of head and neck cancer patient-derived xenografts identifies the mTOR inhibitor everolimus as potential new treatment option. Int J Cancer. 2015;136(12):2940\u20138.","journal-title":"Int J Cancer"},{"issue":"5","key":"6786_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.celrep.2018.10.004","volume":"25","author":"C Karamboulas","year":"2018","unstructured":"Karamboulas C, Bruce JP, Hope AJ, Meens J, Huang SH, Erdmann N, Hyatt E, Pereira K, Goldstein DP, Weinreb I, et al. Patient-Derived Xenografts for Prognostication and Personalized Treatment for Head and Neck Squamous Cell Carcinoma. Cell Rep. 2018;25(5):1318\u20131331.e1314.","journal-title":"Cell Rep"},{"key":"6786_CR13","doi-asserted-by":"crossref","unstructured":"Facompre ND, Sahu V, Montone KT, Harmeyer KM, Nakagawa H, Rustgi AK, Weinstein GS, Gimotty PA, Basu D. Barriers to generating PDX models of HPV-related head and neck cancer. Laryngoscope. 2017;127(12):2777\u201383.","DOI":"10.1002\/lary.26679"},{"issue":"4","key":"6786_CR14","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1158\/1078-0432.CCR-12-2746","volume":"19","author":"RJ Kimple","year":"2013","unstructured":"Kimple RJ, Harari PM, Torres AD, Yang RZ, Soriano BJ, Yu M, Armstrong EA, Blitzer GC, Smith MA, Lorenz LD, et al. Development and characterization of HPV-positive and HPV-negative head and neck squamous cell carcinoma tumorgrafts. Clin Cancer Res. 2013;19(4):855\u201364.","journal-title":"Clin Cancer Res"},{"issue":"8","key":"6786_CR15","doi-asserted-by":"publisher","first-page":"2167","DOI":"10.1016\/j.celrep.2018.07.058","volume":"24","author":"KM Campbell","year":"2018","unstructured":"Campbell KM, Lin T, Zolkind P, Barnell EK, Skidmore ZL, Winkler AE, Law JH, Mardis ER, Wartman LD, Adkins DR, et al. Oral cavity squamous cell carcinoma Xenografts retain complex genotypes and Intertumor molecular heterogeneity. Cell Rep. 2018;24(8):2167\u201378.","journal-title":"Cell Rep"},{"issue":"24","key":"6786_CR16","doi-asserted-by":"publisher","first-page":"7546","DOI":"10.1158\/0008-5472.CAN-14-0826","volume":"74","author":"S Sun","year":"2014","unstructured":"Sun S, Liu S, Duan SZ, Zhang L, Zhou H, Hu Y, Zhou X, Shi C, Zhou R, Zhang Z. Targeting the c-met\/FZD8 signaling axis eliminates patient-derived cancer stem-like cells in head and neck squamous carcinomas. Cancer Res. 2014;74(24):7546\u201359.","journal-title":"Cancer Res"},{"key":"6786_CR17","doi-asserted-by":"publisher","first-page":"14495","DOI":"10.1038\/srep14495","volume":"5","author":"NG Alkema","year":"2015","unstructured":"Alkema NG, Tomar T, Duiker EW, Jan Meersma G, Klip H, van der Zee AG, Wisman GB, de Jong S. Biobanking of patient and patient-derived xenograft ovarian tumour tissue: efficient preservation with low and high fetal calf serum based methods. Sci Rep. 2015;5:14495.","journal-title":"Sci Rep"},{"issue":"1","key":"6786_CR18","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1056\/NEJMoa0912217","volume":"363","author":"KK Ang","year":"2010","unstructured":"Ang KK, Harris J, Wheeler R, Weber R, Rosenthal DI, Nguyen-Tan PF, Westra WH, Chung CH, Jordan RC, Lu C, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24\u201335.","journal-title":"N Engl J Med"},{"issue":"5","key":"6786_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1093\/bioinformatics\/btp698","volume":"26","author":"H Li","year":"2010","unstructured":"Li H, Durbin R. Fast and accurate long-read alignment with burrows-Wheeler transform. Bioinformatics. 2010;26(5):589\u201395.","journal-title":"Bioinformatics"},{"key":"6786_CR20","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1186\/1471-2164-15-1172","volume":"15","author":"KY Tso","year":"2014","unstructured":"Tso KY, Lee SD, Lo KW, Yip KY. Are special read alignment strategies necessary and cost-effective when handling sequencing reads from patient-derived tumor xenografts? BMC Genomics. 2014;15:1172.","journal-title":"BMC Genomics"},{"issue":"3","key":"6786_CR21","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/nbt.2514","volume":"31","author":"K Cibulskis","year":"2013","unstructured":"Cibulskis K, Lawrence MS, Carter SL, Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES, Getz G. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol. 2013;31(3):213\u20139.","journal-title":"Nat Biotechnol"},{"issue":"2","key":"6786_CR22","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ng.3774","volume":"49","author":"M Griffith","year":"2017","unstructured":"Griffith M, Spies NC, Krysiak K, McMichael JF, Coffman AC, Danos AM, Ainscough BJ, Ramirez CA, Rieke DT, Kujan L, et al. CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer. Nat Genet. 2017;49(2):170\u20134.","journal-title":"Nat Genet"},{"issue":"10","key":"6786_CR23","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1038\/nmeth.4000","volume":"13","author":"BJ Ainscough","year":"2016","unstructured":"Ainscough BJ, Griffith M, Coffman AC, Wagner AH, Kunisaki J, Choudhary MN, McMichael JF, Fulton RS, Wilson RK, Griffith OL, et al. DoCM: a database of curated mutations in cancer. Nat Methods. 2016;13(10):806\u20137.","journal-title":"Nat Methods"},{"key":"6786_CR24","doi-asserted-by":"crossref","unstructured":"Lim SM, Cho SH, Hwang IG, Choi JW, Chang H, Ahn MJ, Park KU, Kim JW, Ko YH, Ahn HK, et al. Investigating the feasibility of targeted next-generation sequencing to guide the treatment of head and neck squamous cell carcinoma. Cancer Res Treat. 2019;51(1):300\u201312.","DOI":"10.4143\/crt.2018.012"},{"issue":"18","key":"6786_CR25","doi-asserted-by":"publisher","first-page":"2847","DOI":"10.1093\/bioinformatics\/btw313","volume":"32","author":"Z Gu","year":"2016","unstructured":"Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847\u20139.","journal-title":"Bioinformatics"},{"issue":"5","key":"6786_CR26","first-page":"1165","volume":"6","author":"J Wennerberg","year":"1986","unstructured":"Wennerberg J, Willen R, Biorklund A, Trope C. Histopathological characteristics predictive for growth of squamous cell carcinomas of the head and neck heterotransplanted to nude mice. Anticancer Res. 1986;6(5):1165\u201370.","journal-title":"Anticancer Res"},{"key":"6786_CR27","doi-asserted-by":"crossref","unstructured":"Folaron M, Merzianu M, Duvvuri U, Ferris RL, Seshadri M. Profiling the Stromal and Vascular Heterogeneity in Patient-derived Xenograft Models of Head and Neck Cancer: Impact on Therapeutic Response. Cancers. 2019;11(7):951.","DOI":"10.3390\/cancers11070951"},{"issue":"8","key":"6786_CR28","doi-asserted-by":"publisher","first-page":"e0134346","DOI":"10.1371\/journal.pone.0134346","volume":"10","author":"CX Pan","year":"2015","unstructured":"Pan CX, Zhang H, Tepper CG, Lin TY, Davis RR, Keck J, Ghosh PM, Gill P, Airhart S, Bult C, et al. Development and characterization of bladder Cancer patient-derived Xenografts for molecularly guided targeted therapy. PLoS One. 2015;10(8):e0134346.","journal-title":"PLoS One"},{"issue":"6","key":"6786_CR29","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.celrep.2013.08.022","volume":"4","author":"S Li","year":"2013","unstructured":"Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, He X, Liu S, Hoog J, Lu C, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4(6):1116\u201330.","journal-title":"Cell Rep"},{"issue":"15","key":"6786_CR30","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1158\/0008-5472.CAN-12-4081","volume":"73","author":"X Zhang","year":"2013","unstructured":"Zhang X, Claerhout S, Prat A, Dobrolecki LE, Petrovic I, Lai Q, Landis MD, Wiechmann L, Schiff R, Giuliano M, et al. A renewable tissue resource of phenotypically stable, biologically and ethnically diverse, patient-derived human breast cancer xenograft models. Cancer Res. 2013;73(15):4885\u201397.","journal-title":"Cancer Res"},{"issue":"13","key":"6786_CR31","doi-asserted-by":"publisher","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-07-0078","volume":"13","author":"E Marangoni","year":"2007","unstructured":"Marangoni E, Vincent-Salomon A, Auger N, Degeorges A, Assayag F, de Cremoux P, de Plater L, Guyader C, De Pinieux G, Judde JG, et al. A new model of patient tumor-derived breast cancer xenografts for preclinical assays. Clin Cancer Res. 2007;13(13):3989\u201398.","journal-title":"Clin Cancer Res"},{"issue":"19","key":"6786_CR32","doi-asserted-by":"publisher","first-page":"1944","DOI":"10.1056\/NEJMoa065497","volume":"356","author":"G D'Souza","year":"2007","unstructured":"D'Souza G, Kreimer AR, Viscidi R, Pawlita M, Fakhry C, Koch WM, Westra WH, Gillison ML. Case-control study of human papillomavirus and oropharyngeal cancer. N Engl J Med. 2007;356(19):1944\u201356.","journal-title":"N Engl J Med"},{"issue":"4","key":"6786_CR33","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1200\/JCO.2007.14.1713","volume":"26","author":"AK Chaturvedi","year":"2008","unstructured":"Chaturvedi AK, Engels EA, Anderson WF, Gillison ML. Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. J Clin Oncol. 2008;26(4):612\u20139.","journal-title":"J Clin Oncol"},{"issue":"10","key":"6786_CR34","doi-asserted-by":"publisher","first-page":"2901","DOI":"10.1002\/cncr.23745","volume":"113","author":"AB Ryerson","year":"2008","unstructured":"Ryerson AB, Peters ES, Coughlin SS, Chen VW, Gillison ML, Reichman ME, Wu XC, Chaturvedi AK, Kawaoka K. Burden of potentially human papillomavirus-associated cancers of the oropharynx and Oral cavity in the US, 1998-2003. Cancer. 2008;113(10):2901\u20139.","journal-title":"Cancer"},{"issue":"9","key":"6786_CR35","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1002\/cncr.20998","volume":"103","author":"CH Shiboski","year":"2005","unstructured":"Shiboski CH, Schmidt BL, Jordan RCK. Tongue and tonsil carcinoma - increasing trends in the US population ages 20-44 years. Cancer. 2005;103(9):1843\u20139.","journal-title":"Cancer"},{"key":"6786_CR36","doi-asserted-by":"crossref","unstructured":"The Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature. 2015;517(7536):576\u201382.","DOI":"10.1038\/nature14129"},{"issue":"3","key":"6786_CR37","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1158\/1078-0432.CCR-14-1756","volume":"21","author":"HS Kim","year":"2015","unstructured":"Kim HS, Kwon HJ, Jung I, Yun MR, Ahn MJ, Kang BW, Sun JM, Kim SB, Yoon DH, Park KU, et al. Phase II clinical and exploratory biomarker study of dacomitinib in patients with recurrent and\/or metastatic squamous cell carcinoma of head and neck. Clin Cancer Res. 2015;21(3):544\u201352.","journal-title":"Clin Cancer Res"},{"issue":"3","key":"6786_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/S1470-2045(17)30064-5","volume":"18","author":"D Soulieres","year":"2017","unstructured":"Soulieres D, Faivre S, Mesia R, Remenar E, Li SH, Karpenko A, Dechaphunkul A, Ochsenreither S, Kiss LA, Lin JC, et al. Buparlisib and paclitaxel in patients with platinum-pretreated recurrent or metastatic squamous cell carcinoma of the head and neck (BERIL-1): a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Oncol. 2017;18(3):323\u201335.","journal-title":"Lancet Oncol"},{"issue":"6","key":"6786_CR39","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1158\/2159-8290.CD-16-1396","volume":"7","author":"C Massard","year":"2017","unstructured":"Massard C, Michiels S, Ferte C, Le Deley MC, Lacroix L, Hollebecque A, Verlingue L, Ileana E, Rosellini S, Ammari S, et al. High-throughput genomics and clinical outcome in hard-to-treat advanced cancers: results of the MOSCATO 01 trial. Cancer Discov. 2017;7(6):586\u201395.","journal-title":"Cancer Discov"},{"issue":"8","key":"6786_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrd4694","volume":"14","author":"A Mullard","year":"2015","unstructured":"Mullard A. NCI-MATCH trial pushes cancer umbrella trial paradigm. Nat Rev Drug Discov. 2015;14(8):513\u20135.","journal-title":"Nat Rev Drug Discov"},{"issue":"50","key":"6786_CR41","doi-asserted-by":"publisher","first-page":"19936","DOI":"10.1073\/pnas.0707498104","volume":"104","author":"U McDermott","year":"2007","unstructured":"McDermott U, Sharma SV, Dowell L, Greninger P, Montagut C, Lamb J, Archibald H, Raudales R, Tam A, Lee D, et al. Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling. Proc Natl Acad Sci U S A. 2007;104(50):19936\u201341.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7391","key":"6786_CR42","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, Wilson CJ, Lehar J, Kryukov GV, Sonkin D, et al. The Cancer cell line encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 2012;483(7391):603\u20137.","journal-title":"Nature"},{"issue":"10","key":"6786_CR43","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1054\/bjoc.2001.1796","volume":"84","author":"JI Johnson","year":"2001","unstructured":"Johnson JI, Decker S, Zaharevitz D, Rubinstein LV, Venditti J, Schepartz S, Kalyandrug S, Christian M, Arbuck S, Hollingshead M, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer. 2001;84(10):1424\u201331.","journal-title":"Br J Cancer"},{"issue":"4","key":"6786_CR44","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1038\/labinvest.2008.6","volume":"88","author":"R Hasina","year":"2008","unstructured":"Hasina R, Whipple ME, Martin LE, Kuo WP, Ohno-Machado L, Lingen MW. Angiogenic heterogeneity in head and neck squamous cell carcinoma: biological and therapeutic implications. Lab Invest. 2008;88(4):342\u201353.","journal-title":"Lab Invest"},{"issue":"9","key":"6786_CR45","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","volume":"4","author":"M Hidalgo","year":"2014","unstructured":"Hidalgo M, Amant F, Biankin AV, Budinska E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Maelandsmo GM, et al. Patient-derived Xenograft models: an emerging platform for translational Cancer research. Cancer Discovery. 2014;4(9):998\u20131013.","journal-title":"Cancer Discovery"},{"issue":"6","key":"6786_CR46","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrclinonc.2012.61","volume":"9","author":"JJ Tentler","year":"2012","unstructured":"Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol. 2012;9(6):338\u201350.","journal-title":"Nat Rev Clin Oncol"},{"issue":"17","key":"6786_CR47","doi-asserted-by":"publisher","first-page":"5315","DOI":"10.1158\/0008-5472.CAN-13-1069","volume":"73","author":"D Siolas","year":"2013","unstructured":"Siolas D, Hannon GJ. Patient-derived tumor Xenografts: transforming clinical samples into mouse models. Cancer Res. 2013;73(17):5315\u20139.","journal-title":"Cancer Res"},{"issue":"2","key":"6786_CR48","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/bjc.1978.29","volume":"37","author":"JA Houghton","year":"1978","unstructured":"Houghton JA, Taylor DM. Growth characteristics of human colorectal tumours during serial passage in immune-deprived mice. Br J Cancer. 1978;37(2):213\u201323.","journal-title":"Br J Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06786-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-020-06786-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-06786-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T23:42:49Z","timestamp":1618443769000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-06786-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4,15]]},"references-count":48,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6786"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-06786-5","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4,15]]},"assertion":[{"value":"17 December 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 March 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All applicable international, national, and\/or institutional guidelines for the care and use of animals were followed. All methods were approved by the AAALAC (Association of Assessment and Accreditation of Laboratory Animal Care). All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional research committee. The study was approved by the appropriate Institutional Review Board (4\u20132013-0526), and patient tumor specimens were obtained from the Yonsei University Severance Hospital.All patients to participate in this study provided written informed consent based on Institutional Review Board (4\u20132013-0526).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"316"}}